BRPI0417337A - agentes anti-enxaqueca heterocìclicos - Google Patents
agentes anti-enxaqueca heterocìclicosInfo
- Publication number
- BRPI0417337A BRPI0417337A BRPI0417337-6A BRPI0417337A BRPI0417337A BR PI0417337 A BRPI0417337 A BR PI0417337A BR PI0417337 A BRPI0417337 A BR PI0417337A BR PI0417337 A BRPI0417337 A BR PI0417337A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- methods
- cgrp
- migraine agents
- migraine
- Prior art date
Links
- 229940125684 antimigraine agent Drugs 0.000 title 1
- 239000002282 antimigraine agent Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 abstract 2
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000005796 circulatory shock Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000024883 vasodilation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"AGENTES ANTI-ENXAQUECA HETEROCìCLICOS". A presente invenção se refere a compostos de Fórmula (I) como antagonistas de receptores peptídicos relacionados com o gene da calcitonina ('receptor de CGRP'), composições farmacêuticas compreendendo os mesmos, métodos para identificar os mesmos, métodos de tratamento usando os mesmos e sua aplicação em terapia para tratamento de vasodilatação neurogênica, inflamação neurogênica, enxaqueca e outras cefaléias, agressão térmica, choque circulatório, acessos de calor associados com a menopausa, doenças inflamatórias das vias aéreas, tais como asma e doença pulmonar obstrutiva crónica (COPD), e outras condições cujo tratamento pode ser efetuado pelo antagonismo de receptores de CGRP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52743803P | 2003-12-05 | 2003-12-05 | |
US11/004,706 US7569578B2 (en) | 2003-12-05 | 2004-12-03 | Heterocyclic anti-migraine agents |
PCT/US2004/040721 WO2005056550A2 (en) | 2003-12-05 | 2004-12-06 | Heterocyclic anti-migraine agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0417337A true BRPI0417337A (pt) | 2007-04-17 |
Family
ID=34680800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0417337-6A BRPI0417337A (pt) | 2003-12-05 | 2004-12-06 | agentes anti-enxaqueca heterocìclicos |
Country Status (17)
Country | Link |
---|---|
US (1) | US7569578B2 (pt) |
EP (1) | EP1689738A2 (pt) |
JP (1) | JP2007516967A (pt) |
KR (1) | KR20070026339A (pt) |
AR (1) | AR046787A1 (pt) |
AU (1) | AU2004297230A1 (pt) |
BR (1) | BRPI0417337A (pt) |
CA (1) | CA2549401A1 (pt) |
CO (1) | CO5690595A2 (pt) |
IL (1) | IL176043A0 (pt) |
IS (1) | IS8483A (pt) |
MX (1) | MXPA06005970A (pt) |
NO (1) | NO20062489L (pt) |
PE (1) | PE20050670A1 (pt) |
RU (1) | RU2006124026A (pt) |
TW (1) | TW200524601A (pt) |
WO (1) | WO2005056550A2 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0311812B8 (pt) * | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US7842808B2 (en) * | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
JP4769082B2 (ja) * | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) * | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
US7834007B2 (en) * | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
US8067447B2 (en) | 2006-11-01 | 2011-11-29 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US8198311B2 (en) * | 2006-11-01 | 2012-06-12 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
EP2294062B1 (en) | 2008-06-09 | 2013-08-21 | Bayer Intellectual Property GmbH | Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof |
DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
DE102008038220A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
EP2398790B1 (en) | 2009-02-18 | 2013-07-03 | Bayer Intellectual Property GmbH | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof |
JP5674211B2 (ja) | 2009-07-10 | 2015-02-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | インダゾリル置換のジヒドロイソオキサゾロピリジンおよびその使用方法 |
EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
CN104662015B (zh) | 2012-06-20 | 2017-03-29 | 诺华股份有限公司 | 补体途径调节剂及其用途 |
WO2014062548A1 (en) | 2012-10-18 | 2014-04-24 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
EA030814B1 (ru) | 2012-11-20 | 2018-10-31 | Мериал, Инк. | Антигельминтные соединения, композиции и способы их применения |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
HRP20220258T1 (hr) * | 2015-03-10 | 2022-04-29 | Aurigene Discovery Technologies Limited | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
WO2019073399A1 (en) | 2017-10-11 | 2019-04-18 | Aurigene Discovery Technologies Limited | CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE SUBSTITUTED IN POSITION 3 |
US11497734B2 (en) | 2017-11-03 | 2022-11-15 | Aurigene Discovery Technologies Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
JP7378395B2 (ja) | 2017-11-06 | 2023-11-13 | オーリジーン オンコロジー リミテッド | 免疫調節のためのコンジョイントセラピー |
EP3737699A1 (en) | 2018-01-12 | 2020-11-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
WO2022172829A1 (ja) * | 2021-02-15 | 2022-08-18 | 株式会社カネカ | 光学活性インダゾリルアラニン又はインダゾリルアルデヒドの製造方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0851759A4 (en) | 1995-09-05 | 2000-12-06 | Smithkline Beecham Corp | COMPOUNDS AND RELATED METHODS |
CA2264942A1 (en) | 1996-09-09 | 1998-03-12 | Smithkline Beecham Corporation | Compounds and methods |
EA004037B1 (ru) | 1996-09-10 | 2003-12-25 | Др. Карл Томэ ГмбХ | Модифицированные аминокислоты и лекарственное средство на их основе |
WO1998056779A1 (en) | 1997-06-13 | 1998-12-17 | Smithkline Beecham Corporation | 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
AU5265599A (en) | 1998-04-08 | 1999-11-01 | Takeda Chemical Industries Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
EP1117662A1 (en) | 1998-09-30 | 2001-07-25 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6313097B1 (en) | 1999-03-02 | 2001-11-06 | Boehringer Ingelheim Pharma Kg | Antagonists of calcitonin gene-related peptide |
US6521609B1 (en) | 1999-08-10 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes |
CA2386517A1 (en) | 1999-10-07 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Amine derivatives |
DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19963868A1 (de) | 1999-12-30 | 2001-07-12 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU7909801A (en) | 2000-08-01 | 2002-02-13 | Sod Conseils Rech Applic | Imidazolyl derivatives |
US20030181462A1 (en) | 2001-08-17 | 2003-09-25 | Boehringer Ingelheim Pharma Kg | Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine |
DE60234944D1 (de) | 2001-09-27 | 2010-02-11 | Merck & Co Inc | Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren |
DE10206770A1 (de) | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096 |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
US20040014679A1 (en) | 2002-02-20 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof |
DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7026312B2 (en) | 2002-03-14 | 2006-04-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
BRPI0311812B8 (pt) | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
US20040076587A1 (en) | 2002-06-19 | 2004-04-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7202251B2 (en) | 2003-03-14 | 2007-04-10 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin CGRP receptor antagonists |
ATE556060T1 (de) | 2003-03-14 | 2012-05-15 | Merck Sharp & Dohme | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten |
WO2004087649A2 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
US7189722B2 (en) | 2003-03-14 | 2007-03-13 | Merck & Co., Inc. | Aryl spirohydantoin CGRP receptor antagonists |
EP1613368B1 (en) | 2003-03-14 | 2011-11-30 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin cgrp receptor antagonists |
US20040248816A1 (en) | 2003-04-01 | 2004-12-09 | Boehringer Ingelheim International Gmbh | Treatment of migraine |
DE602004027021D1 (de) | 2003-04-15 | 2010-06-17 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
US7196079B2 (en) | 2003-06-26 | 2007-03-27 | Merck & Co, Inc. | Benzodiazepine CGRP receptor antagonists |
US20050032783A1 (en) | 2003-07-07 | 2005-02-10 | Boehringer Ingelheim International Gmbh | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients |
JP2007523870A (ja) | 2003-07-15 | 2007-08-23 | メルク エンド カムパニー インコーポレーテッド | ヒドロキシピリジンcgrp受容体拮抗薬 |
US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
CA2549330A1 (en) | 2003-12-05 | 2005-07-21 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
CA2554351A1 (en) | 2004-01-29 | 2005-08-11 | Merck & Co., Inc. | Cgrp receptor antagonists |
WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004018796A1 (de) | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7279471B2 (en) | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018794A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
WO2005102322A1 (de) | 2004-04-20 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne |
US20050233980A1 (en) | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7696195B2 (en) | 2004-04-22 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004027912A1 (de) | 2004-06-09 | 2005-12-29 | Grünenthal GmbH | Substituierte Cyclopenten-Verbindungen |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
-
2004
- 2004-12-03 AR ARP040104529A patent/AR046787A1/es unknown
- 2004-12-03 US US11/004,706 patent/US7569578B2/en active Active
- 2004-12-03 TW TW093137539A patent/TW200524601A/zh unknown
- 2004-12-06 RU RU2006124026/04A patent/RU2006124026A/ru not_active Application Discontinuation
- 2004-12-06 MX MXPA06005970A patent/MXPA06005970A/es not_active Application Discontinuation
- 2004-12-06 JP JP2006542841A patent/JP2007516967A/ja not_active Withdrawn
- 2004-12-06 KR KR1020067010916A patent/KR20070026339A/ko not_active Application Discontinuation
- 2004-12-06 CA CA002549401A patent/CA2549401A1/en not_active Abandoned
- 2004-12-06 EP EP04813096A patent/EP1689738A2/en not_active Withdrawn
- 2004-12-06 PE PE2004001195A patent/PE20050670A1/es not_active Application Discontinuation
- 2004-12-06 BR BRPI0417337-6A patent/BRPI0417337A/pt not_active IP Right Cessation
- 2004-12-06 WO PCT/US2004/040721 patent/WO2005056550A2/en active Application Filing
- 2004-12-06 AU AU2004297230A patent/AU2004297230A1/en not_active Abandoned
-
2006
- 2006-05-26 IS IS8483A patent/IS8483A/is unknown
- 2006-05-31 NO NO20062489A patent/NO20062489L/no not_active Application Discontinuation
- 2006-05-31 IL IL176043A patent/IL176043A0/en unknown
- 2006-06-01 CO CO06052775A patent/CO5690595A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2006124026A (ru) | 2008-01-27 |
IS8483A (is) | 2006-05-26 |
AR046787A1 (es) | 2005-12-21 |
EP1689738A2 (en) | 2006-08-16 |
JP2007516967A (ja) | 2007-06-28 |
AU2004297230A1 (en) | 2005-06-23 |
WO2005056550A3 (en) | 2005-07-14 |
MXPA06005970A (es) | 2006-07-06 |
US7569578B2 (en) | 2009-08-04 |
NO20062489L (no) | 2006-06-14 |
CO5690595A2 (es) | 2006-10-31 |
CA2549401A1 (en) | 2005-06-23 |
US20050153959A1 (en) | 2005-07-14 |
PE20050670A1 (es) | 2005-09-25 |
WO2005056550A2 (en) | 2005-06-23 |
IL176043A0 (en) | 2006-10-05 |
TW200524601A (en) | 2005-08-01 |
KR20070026339A (ko) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0417337A (pt) | agentes anti-enxaqueca heterocìclicos | |
BR0311812A (pt) | Antagonistas de receptor de peptìdeo relacionado com o gene de calcitonina | |
BRPI0509341A (pt) | anatagonistas de cgrp hetorocìclicos para o tratamento de enxaqueca | |
BR0318637A (pt) | antagonistas de receptores de peptìdios relacionados com o gene de calcitonina | |
EA201270561A1 (ru) | Антагонисты рецептора cgrp | |
AU2009299554B8 (en) | P38 MAP kinase inhibitors | |
EP2582432B1 (en) | Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections | |
BRPI0517965A (pt) | compostos restritos como antagonistas de receptor de cgrp | |
AR071314A1 (es) | Antagonistas de receptor de cgrp | |
KR102341064B1 (ko) | 리소포스파티드산 수용체 1 (lpar1) 억제제 화합물 | |
BRPI0515524A (pt) | compostos quìmicos | |
EA201270751A1 (ru) | Антагонист рецептора cgrp | |
AU2014214355B2 (en) | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | |
BR112021022099A2 (pt) | Derivados de amino quinazolina como inibidores de p2x3 | |
BRPI0607652A2 (pt) | acil hidrazidas como inibidoras de quinase, em particular para sgk | |
CN101684098A (zh) | 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用 | |
WO2007130927A3 (en) | Condensed tricyclic compounds as cgrp-receptor antagonists | |
NO20084564L (no) | Stramme "Constrained" forbindelser som CGRP-reseptor antagonister | |
Giardina et al. | A novel, nonpeptidic, orally active bivalent inhibitor of human β-tryptase | |
US11207296B2 (en) | XPA inhibitor compounds and their use | |
HRP20060236A2 (en) | Calcitonin gene related peptide receptor antagonists | |
TH87766B (th) | สารต้านไมเกรนประเภทเฮตเทอโรไซคลิค | |
CY1114902T1 (el) | Ανταγωνιστες cgrp υποδοχεα | |
TH87766A (th) | สารต้านไมเกรนประเภทเฮตเทอโรไซคลิค | |
TH78134A (th) | แอนตะกอนิสต์ของรีเซฟเตอร์สำหรับแคลซิโทนินรีเลตเปปไทด์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |